We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Rallybio

News List

Rallybio Corporation Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares firstwordpharma
August 03, 2021
Rallybio Corporation today announced the closing of its initial public offering of 7,130,000 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 930,000 additional shares of common stock.
Rare disease biotech Rallybio sets terms for $81 million IPO firstwordpharma
July 23, 2021
Rallybio plans to raise $81 million in its initial public offering by offering 5.8 million shares at a price range of $13 to $15, as reported by NASDAQ.
Rare disease biotech Rallybio files for a $100 million IPO firstwordpharma
July 06, 2021
Rallybio has filed with the SEC to raise up to $100 million in an initial public offering, reported Renaissance Capital.
Rallybio Established by Industry Leaders with $37.0 Million in Series A Financing to Develop Transformative Therapies for Patients with Severe and Rare Diseases biospace
April 26, 2018
Rallybio, LLC today announced that it has secured $37.0 million in Series A funding.
Former Alexion Execs Launch Rare Disease Company Rallybio biospace
April 26, 2018
With $37 million in its pocket a new player has emerged to develop treatments for rare diseases.